The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial
Abstract
IMPORTANCE: The current recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-eluting stent. However, the optimal duration of dual antiplatelet therapy with specific types of drug-eluting stents remains unknown. OBJECTIVE: To assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) with zotarolimus-eluting stents. DESIGN, SETTING, AND PATIENTS: The OPTIMIZE trial was an open-label, active-controlled, 1:1 randomized noninferiority study including 3119 patients in 33 sites in Brazil between April 2010 and March 2012. Clinical follow-up was performed at 1, 3, 6, and 12 months. Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents. INTERVENTIONS: After PCI with zotarolimus-eluting stents, patients were prescribed aspirin (100-200 mg daily) and clopidogrel (75 mg daily) for 3 months (n = 1563) or 12 months (n = 1556), unless contraindicated because of occurrence of an end point. MAIN OUTCOMES AND MEASURES: The primary end point was net adverse clinical and cerebral events (NACCE; a composite of all-cause death, myocardial infarction [MI], stroke, or major bleeding); the expected event rate at 1 year was 9%, with a noninferiority margin of 2.7%. Secondary end points were major adverse cardiac events (MACE; a composite of all-cause death, MI, emergent coronary artery bypass graft surgery, or target lesion revascularization) and Academic Research Consortium definite or probable stent thrombosis. RESULTS: NACCE occurred in 93 patients receiving short-term and 90 patients receiving long-term therapy (6.0% vs 5.8%, respectively; risk difference, 0.17 [95% CI, -1.52 to 1.86]; P = .002 for noninferiority). Kaplan-Meier estimates demonstrated MACE rates at 1 year of 8.3% (128) in the short-term group and 7.4% (114) in the long-term group (HR, 1.12 [95% CI, 0.87-1.45]). Between 91 and 360 days, no statistically significant association was observed for NACCE (39 [2.6%] vs 38 [2.6%] for the short- and long-term groups, respectively; HR, 1.03 [95% CI, 0.66-1.60]), MACE (78 [5.3%] vs 64 [4.3%]; HR, 1.22 [95% CI, 0.88-1.70]), or stent thrombosis (4 [0.3%] vs 1 [0.1%]; HR, 3.97 [95% CI, 0.44-35.49]). CONCLUSIONS AND RELEVANCE: In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01113372.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C., Kukreja, N., Jüni, P., Sianos, G., Hellige, G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60314-6 · Cited by 1,757
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction
Fröbert, O., Lagerqvist, B., Olivecrona, G. K., Omerovic, E., Gudnason, T., Maeng, M., Aasa, M., Angerås, O., Calais, F., Danielewicz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1308789 · Cited by 1,151
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
Stone, G. W., Rizvi, A., Newman, W., Mastali, K., Wang, J. C., Caputo, R., Doostzadeh, J., Cao, S., Simonton, C. A., Sudhir, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910496 · Cited by 902
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
Eisenstein, E. L., Anstrom, K. J., Kong, D. F., Shaw, L. K., Tuttle, R. H., Mark, D. B., Kramer, J. M., Harrington, R. A., Matchar, D. B., Kandzari, D. E., et al. (2007) · JAMA · doi:10.1001/jama.297.2.joc60179 · Cited by 870
Valgimigli, M., Campo, G., Monti, M., Vranckx, P., Percoco, G., Tumscitz, C., Castriota, F., Colombo, F., Tebaldi, M., Fucà, G., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.071589 · Cited by 672
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
Serruys, P. W., Silber, S., Garg, S., van Geuns, R. J., Richardt, G., Buszman, P. E., Kelbæk, H., van Boven, A. J., Hofma, S. H., Linke, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004130 · Cited by 670
A New Strategy for Discontinuation of Dual Antiplatelet Therapy
Kim, B.-K., Hong, M.-K., Shin, D.-H., Nam, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Kang, T.-S., Park, B.-E., Kang, W.-C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.043 · Cited by 646
Gwon, H.-C., Hahn, J.-Y., Park, K. W., Song, Y. B., Chae, I.-H., Lim, D.-S., Han, K.-R., Choi, J.-H., Choi, S.-H., Kang, H.-J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.059022 · Cited by 614
Kirtane, A. J., Gupta, A., Iyengar, S., Moses, J. W., Leon, M. B., Applegate, R., Brodie, B., Hannan, E., Harjai, K., Jensen, L. O., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.826479 · Cited by 577
Bangalore, S., Kumar, S., Fusaro, M., Amoroso, N., Attubato, M. J., Feit, F., Bhatt, D. L., & Slater, J. (2012) · Circulation · doi:10.1161/circulationaha.112.097014 · Cited by 574
Sabate, M., Cequier, A., Iñiguez, A., Serra, A., Hernandez-Antolin, R., Mainar, V., Valgimigli, M., Tespili, M., den Heijer, P., Bethencourt, A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61223-9 · Cited by 462
Airoldi, F., Colombo, A., Morici, N., Latib, A., Cosgrave, J., Buellesfeld, L., Bonizzoni, E., Carlino, M., Gerckens, U., Godino, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.686048 · Cited by 455
Vranckx, P., Cutlip, D. E., Mehran, R., Kint, P.-P., Silber, S., Windecker, S., & Serruys, P. W. J. C. (2010) · EuroIntervention · doi:10.4244/eijv5i7a146 · Cited by 281
Schulz, S., Schuster, T., Mehilli, J., Byrne, R. A., Ellert, J., Massberg, S., Goedel, J., Bruskina, O., Ulm, K., Schomig, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp275 · Cited by 234
Mauri, L., Kereiakes, D. J., Normand, S.-L. T., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Bangalore, S., Cutlip, D. E., Pencina, M., & Massaro, J. M. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.038 · Cited by 170
Berger, P. B., Kleiman, N. S., Pencina, M. J., Hsieh, W.-H., Steinhubl, S. R., Jeremias, A., Sonel, A., Browne, K., Barseness, G., & Cohen, D. J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.03.021 · Cited by 162
Camenzind, E., Wijns, W. C., Mauri, L., Kurowski, V., Parikh, K. H., Gao, R., Bode, C., Greenwood, J. P., Boersma, E. H., Vranckx, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61336-1 · Cited by 156
Valgimigli, M., Borghesi, M., Tebaldi, M., Vranckx, P., Parrinello, G., Ferrari, R., for the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Investigators, Valgimigli, M., Campo, G., Percoco, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs460 · Cited by 108
Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents
Park, S., Park, D., Kim, Y., Kang, S., Lee, S., Lee, C. W., Han, K., Park, S., Yun, S.-C., Lee, S.-G., et al. (2011) · Survey of Anesthesiology · doi:10.1097/01.sa.0000391589.20506.f0 · Cited by 94
Byrne, R. A., Schulz, S., Mehilli, J., Iijima, R., Maßberg, S., Neumann, F., Berg, J. M. T., Schömig, A., & Kastrati, A. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.12.019 · Cited by 93
Roy, P. K., Bonello, L., Torguson, R., Okabe, T., Slottow, T. L. P., Steinberg, D. H., Kaneshige, K., Xue, Z., Satler, L. F., Kent, K. M., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.038 · Cited by 60
Ben‐Dor, I., Torguson, R., Scheinowitz, M., Li, Y., Delhaye, C., Wakabayashi, K., Maluenda, G., Syed, A. I., Collins, S. D., González, M. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.01.016 · Cited by 53
Topol, E. J., Armstrong, P. W., de Werf, F. V., Kleiman, N. S., Lee, K. L., Morris, D. L., Simoons, M. L., Barbash, G. I., White, H. D., & Califf, R. M. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90312-b · Cited by 49
EXAMINATION of new drug-eluting stents—top of the class!
Bhatt, D. L. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61021-6 · Cited by 36
Endothelial progenitor cell response to antiproliferative drug exposure
Banerjee, S., Xu, H., Fuh, E., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.025 · Cited by 20
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Metadata
- Authors
- Feres, F.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-10-31
- Volume
- 310
- Issue
- 23
- Pages
- 2510-22
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2103798306
- Cited by
- 589
- References
- 34
- FWCI
- 54.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.